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Background: The purpose of this study was to investigate the effectiveness and stability of long-term lithium
treatment in a prospective, international, multicenter cohort of bipolar patients in a naturalistic setting.
Methods: Patients were selected according to DSM IV criteria for bipolar disorder and required long-term
treatment. They were prospectively followed and documented in five centers belonging to the International Group
for the Study of Lithium-Treated Patients. This was a prospective cohort study without a comparison group. Lithium
treatment was administered in a naturalistic and specialized outpatient setting. All patients underwent a
comprehensive psychiatric examination, which included the use of standard rating scales, as well as an evaluation
of clinical course based on the morbidity index (MI).
Wald tests were used to assess the significance of fixed effects and covariates when analyzing the relationship
between depressive, manic, and total morbidity index and several characteristics of illness course.
Results and discussion: A total of 346 patients with bipolar disorder I or II were followed for a mean period of
10.0 years (standard deviation (SD) 6.2, range 1 to 20). The morbidity index remained stable over time: the mean MI
was 0.125 (SD 0.299) in year 1 and 0.110 (SD 0.267) in year 20. The MI was not associated with the duration of
lithium treatment, the number or frequency of episodes prior to treatment, or latency from the onset of bipolar
disorder to the start of lithium treatment. The drop-out rate was high over the study period. Our findings suggest
that long-term response to lithium maintenance treatment remains stable over time.
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Lithium is recommended in all major international guide-
lines as a first-line prophylactic treatment for bipolar dis-
order (American Psychiatric Association 2002; Grunze
et al. 2004; Crossley et al. 2006; Yatham et al. 2013; DGBS,
DGPPN 2012; Grof and Müller-Oerlinghausen 2009), and
its efficacy in this context has been demonstrated in meta-
analyses of controlled studies (Burgess et al. 2001; Geddes
et al. 2004; Geddes and Goodwin 2006; Licht 2012). In
naturalistic settings, however, the effectiveness of long-
term lithium treatment has been reported to be much
lower (Surtees and Barkley 1994; Harrow et al. 1990;
Goldberg et al. 1995; Keller et al. 1993; Licht et al. 2008),
and to even diminish over time (Post et al. 1993; Maj et al.* Correspondence: anne.berghoefer@charite.de
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in any medium, provided the original work is p1989a). Maj and coworkers analyzed the course of illness
in 43 bipolar patients who had been successfully treated
with lithium for 2 years. During a follow-up period of 5
years, a substantial number of patients experienced recur-
rences despite their having been initially classified as re-
sponders to lithium treatment. The authors interpreted
this as an indication that it may not be possible to achieve
long-term stability with lithium prophylaxis (Maj et al.
1989a). Post and coworkers retrospectively assessed the
course of illness in 66 lithium-refractory patients with
affective disorder and found that a substantial number of
those who initially showed a complete or partial response
to lithium experienced a gradual loss of efficacy over time
(Post et al. 1993). However, recent observational studies
show a general superiority of lithium compared to alterna-
tive mood stabilizers in clinical practice (Kessing et al.
2012; Kessing et al. 2011; Nivoli et al. 2010; Garnham
et al. 2007).is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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across studies have been variously attributed to methodo-
logical disparities (Deshauer et al. 2005; Coryell 2009), a
broadening of the diagnostic criteria for bipolar disorder
(Grof et al. 1993; Grof et al. 1995; Grof 1998), or changes
in the course of illness over long periods (Goodwin 1999).
The present study investigated a prospective, multi-
center cohort of patients with bipolar disorder. Its aim
was to determine whether the long-term effectiveness of
lithium prophylaxis remains stable over time. A sub-
group of 242 patients from this sample has been ana-
lyzed elsewhere with regard to the influence of atypical
symptoms (Berghöfer et al. 2008). Another subgroup of
336 patients was included in an analysis of recurrence
risk that applied extended Cox regression models, which
allow for the use all follow-up data on diseases with
multiple episodes, to examine the influence of atypical
features on time to recurrence (Pfennig et al. 2010).
Methods
Inclusion criteria
Patients were selected based on classical criteria for
diagnosing bipolar disorder. When the first patients were
included in the study in the 1980s, the eighth revision of
the International Classification of Diseases (ICD-8)
(World Health Organization 1969) was in use. The ICD-
8 was later replaced by the ICD-9 (World Health
Organization 1979). After 1994, all of the patients in the
study were rediagnosed according to DSM IV (American
Psychiatric Association 1993). All patients required
long-term treatment, as defined by the presence of at
least one manic episode or at least two episodes of any
type in the patient's history. Patients were included in
the study if they had been treated continuously with lith-
ium for at least 1 year and were at least 18 years of age.
From the time of their presentation at the clinic until
2004, all patients were followed up in the outpatient de-
partments of five participating International Group for the
Study of Lithium-Treated Patients (IGSLi) centers (Berlin,
Germany; Halifax, Hamilton, and Ottawa, Canada; Poznan,
Poland). These centers were founded in the 1980s and
followed a standard research program consisting of long-
term prophylactic treatment with lithium and other drugs
for the management of unipolar mood disorder, bipolar
mood disorder, or schizoaffective disorder (www.igsli.org;
Müller-Oerlinghausen et al. 1994; Alda et al. 2000).
Patient assessment
During each visit, patients were evaluated by a psych-
iatrist, who (a) performed a psychiatric assessment, tak-
ing account of the patient's case history and past
medication; (b) administered one or more standard
mood rating scales (Bech-Rafaelsen Melancholia and
Mania Scales (Bech et al. 1979; Bech et al. 1978),Hamilton-Depression-Scale (HAMILTON 1960), Young
Mania Scale (1978)); (c) performed a physical examin-
ation; (d) recorded any adverse events; and (e) pre-
scribed any clinical or pharmacological interventions he
or she felt was necessary. Serum lithium levels were also
obtained. Patients averaged seven to eight visits each
year, depending on comorbidity, severity of illness, and
age. The number of visits per year was greater than in
normal outpatient settings, facilitating optimal control of
patients’ long-term prophylaxis. Psychiatric nurses and
social workers were available to provide support during
additional, unscheduled visits.
Before enrolling in the prospective cohort, patients
were thoroughly informed about the study procedures,
treatment, and possible side effects, and all participants
gave written, informed consent. The study was approved
by local research ethics committees in jurisdictions in
which such approval was necessary. In the Poznan study
center, the study was approved by the bioethics commit-
tee, Poznan University of Medical Sciences. The center
in Ottawa had an umbrella approval from the Research
ethics committee for the analysis of clinical data of
lithium-treated patients (anonymously, with names re-
moved). The center in Halifax had an approval from the
ethics committee at Capital District Health Authority,
Nova Scotia. In the Berlin center, an approval was not
necessary because the subjects provided written in-
formed consent to the anonymous and aggregate scien-
tific use of data from their confidential medical records
when admitted to the clinic.
The onset of bipolar disorder was defined as the first
recorded diagnosis of bipolar disorder or, if this was
lacking, as the first recorded symptoms clearly related to
bipolar disorder. In turn, a recurrent episode was de-
fined as the presence, in a previously remitted patient, of
symptoms that required either psychotherapeutic or psy-
chopharmacological treatment. All recurrences were
recorded and graded in terms of severity, polarity, and
duration. Finally, remission was defined as the absence of
affective symptoms, as measured using standard mood
rating scales. All data were collected prospectively.
First introduced by Coppen and Abou-Saleh (1982),
the morbidity index (MI) was used in the present study
as the outcome measure and includes severity and
length of episodes. Severity is rated in a semiquantitative
manner using three different degrees: symptoms that do
not require treatment are rated as degree 1; symptoms
that require psychotherapeutic or psychopharmacologi-
cal treatment for acute affective illness but are manage-
able in an outpatient setting are rated as degree 2; and
symptoms necessitating inpatient treatment for acute
affective illness are rated as degree 3. We included
symptoms of degrees 2 and 3 in the analysis and calcu-
lated the MI using the following formula:
e 2Þ 2þ no:of weeks with degree 3ð Þ 3
52 weeks
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For each year, the MI was calculated for all affective
episodes (MItotal) and also separately for depressive epi-
sodes (MIdep) and manic episodes (MIman). To remain in
the study, patients were required to demonstrate suffi-
cient compliance, which was defined as maintaining
serum lithium levels of at least 0.5 mmol/L throughout
the documentation period.
Antipsychotics, antidepressants, or anticonvulsants ad-
ministered in addition to lithium were not regarded as
prophylactic medication and were not included in the
statistical analysis (a) if they were administered as part
of maintenance treatment (i.e., in addition to lithium
during the first 3 months after remission for the purpose
of stabilizing the patient) or (b) if they were adminis-
tered as acute treatment (i.e., in addition to lithium at
any point 4 or more months after remission to manage
new symptoms). In the latter case, weeks during which
acute treatment with antipsychotics, antidepressants, or
anticonvulsants was necessary were rated as degree 2
and were included in the morbidity index. In all other
cases, treatment with drugs from any of these three drug
categories was considered to be prophylactic in nature.
Finally, other drugs, such as benzodiazepines, were not
regarded as additional prophylactic medication, and no
data on their use were recorded.Statistical analysis
Data were analyzed using BMDP (Biomedical Computer
Programs) Statistical Software, Inc. (Cary, NC, USA), re-
lease 8.0. Unbalanced repeated measures regression
models with structured covariance matrices were applied
(module 5V in BMDP) to assess the impact of treatment
duration on the yearly MI (within subject measure). Sep-
arate calculations were made for MItotal, MIdep, and
MIman. Maximum likelihood was used to estimate pa-
rameters, with the expected response values being
expressed as a linear function of the parameters. The
main advantage of this approach was that all subjects
could be included regardless of their duration of treat-
ment. Model selection was based on optimization of
Akaike's information criterion (AIC) (Akaike 1973). The
significance of the independent variables was estimated
using the Wald test. A 5% level of significance was
established with two-tailed tests. Using the same
method, it was possible to examine the impact of the
number of episodes before the start of lithium treatment,
as well as of treatment delay, on the MI. Finally, inde-
pendent variables were modeled in this analysis as
covariates.Results
In the present study, a total of 346 patients were
followed up for a mean period of 10 years (range, 1 to
20 years) on lithium treatment (Figure 1). The number of
subjects varied between the participating treatment cen-
ters (Berlin n = 151, Halifax n = 35, Hamilton n = 14,
Ottawa n = 75, and Poznan n = 71). Patients' baseline
characteristics are given in Table 1. The mean age at the
onset of bipolar disorder was 29, and lithium treatment
was initiated with a mean latency of 10 years. For all 346
patients, the mean MItotal decreased slightly (i.e., from
0.125 to 0.110) over the 20-year observation period.
For long-term stabilization, a total of 152 patients re-
ceived concomitant treatment with antidepressants, anti-
psychotics, or anticonvulsants. The mean period of
concomitant treatment with a drug from one of these
three categories was 22.4 weeks per year (Table 1).
Altogether, 194 patients remained on lithium monother-
apy for their entire follow-up period.
The results of the repeated measures regression did
not show a change in the MItotal, MIdep, or MIman in the
course of the study (see Table 2). There were also no sig-
nificant associations between the number of episodes be-
fore the start of lithium treatment, the latency between
the onset of illness onset and the start of lithium treat-
ment, and the MItotal, MIdep, or MIman (see Table 2).
Many patients dropped out of the study during the
follow-up period. In total, 165 subjects were observed
for at least 10 years, 93 for at least 15 years, and 45 for
at least 20 years. Patients left the study for one of four
reasons: (1) they had been in treatment for less than 20
years by the end of the study; (2) lithium side effects or
interactions with a drug prescribed for a somatic comor-
bidity caused them to switch to another long-term
prophylactic agent; (3) they switched to another out-
patient clinic or moved and were lost to follow-up; or
(4) they died. In patients who left the study, the MIs for
the year of drop-out were not higher than the mean MI
from the preceding years (t test, all P values = n.s.).Discussion
In the present study, the MIs remained stable through-
out the observation period, confirming that the course
of illness also remained stable over time in this subgroup
of bipolar patients receiving prophylactic lithium treat-
ment. No association could be found between the MIs
and the number of episodes before the start of lithium
treatment or the latency between the onset of illness and
the start of lithium treatment.
Figure 1 Morbidity index over 20-year observation period. Black lines show mean (SD) morbidity index for all affective episodes (MItotal); gray
bars show number of subjects in the analysis contributing to the morbidity index each year.
Table 1 Baseline characteristics of the 346 study subjects
Men, n (%) 147 (42.5)
Women, n (%) 199 (57.5)
DSM IV diagnosis, n (%)
Bipolar I 270 (78.0)
Bipolar II 76 (22.0)
Length of follow-up period (year, SD, range) 10.0 (6.2, 1 to 20)
Age at onset of bipolar disorder (year, SD, range) 29.2 (11.0, 11 to 66)
Latency before start of lithium treatment
(year, SD, range)
9.7 (9.3, 0 to 44)
Number of episodes before start of lithium
treatment (n, SD, range)
5.5 (4.9, 0 to 40)
Comedication in all 346 patients (mean number of
weeks [per follow-up year] during which any drugs
from three different drug categories were
administered; n, SD, range)
Total 9.8 (17.7, 0 to 91)
Antipsychotics 2.5 (7.9, 0 to 52)
Antidepressants 3.5 (9.4, 0 to 52)
Anticonvulsants 3.8 (10.5, 0 to 52)
Comedication in 152 patients without lithium
monotherapy (mean number of weeks
[per follow-up year] during which any drugs
from three different drug categories were
administered; n, SD, range)
Total 22.4 (20.9, 0 to 91)
Antipsychotics 5.6 (11.1, 0 to 52)
Antidepressants 8.0 (12.9, 0 to 52)
Anticonvulsants 8.8 (14.4, 0 to 52)
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several respects to investigations that have demonstrated
poor stability with long-term lithium treatment. Many of
the previous prospective studies on lithium treatment
have had relatively short observation periods (i.e., less
than 2 years in duration). Indeed, only a few have had
longer observation periods, i.e., extending up to 5 years
(Maj et al. 1989b; Maj et al. 1998; Maj 2003) or 7 years
(Vestergaard and Schou 1988). In the present study,
however, data were collected over a much longer period,
covering up to 20 years.
Although other studies have assessed large cohorts
over long observation periods, they have not focused on
the long-term stability of prophylactic lithium treatment.
For example, the mood disorders center in Sardinia, a
Stanley Foundation Bipolar Network research center
(Post et al. 2001; Suppes et al. 2001), evaluated a large
cohort of lithium patients comparable in size to the
IGSLI cohort. Tondo and coworkers presented compre-
hensive data on the long-term course of their lithium-
treated patients within the Sardinian cohort (Tondo
et al. 1998; Baldessarini et al. 2000). The results of an
analysis over a mean treatment period of 6 years show a
substantial improvement in the course of illness during
long-term lithium treatment compared to the period be-
fore lithium treatment was initiated, although complete
protection against affective episodes was uncommon.
However, the issue of stability over time in patients on
long-term lithium treatment was not addressed in this
analysis (Tondo et al. 2001). Rybakowski and coworkers
analyzed the efficacy of long-term lithium treatment,
comparing the pre-index period with a post-index lith-
ium treatment period of 10 years (Rybakowski et al.
2001). The study examined whether the effectiveness of
Table 2 Relationship between depressive, manic, and total morbidity index and several characteristics of illness course
(Wald tests for significance of fixed effects and covariates)
Parameter Chi-square P
Total morbidity index
Year of treatment; df = 19 19.847 0.404
Year of treatment × group membership interaction; df = 19 17.658 0.545
Number of episodes before index; df = 1 0.602 0.438
Number of recurrences before index; df = 1 0.002 0.963
Latency between onset of illness and start of lithium treatment; df = 1 1.991 0.158
Depressive morbidity index
Year of treatment; df = 19 26.112 0.127
Year of treatment × group membership interaction; df = 19 12.208 0.877
Number of episodes before index; df = 1 0.304 0.581
Number of recurrences before index; df = 1 0.773 0.379
Latency between onset of illness and start of lithium treatment; df = 1 2.778 0.096
Manic morbidity index
Year of treatment; df = 19 22.963 0.239
Year of treatment × group membership interaction; df = 19 16.271 0.639
Number of episodes before index; df = 1 0.305 0.581
Number of recurrences before index; df =1 2.105 0.147
Latency between onset of illness and start of lithium treatment; df = 1 0.013 0.908
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the 1980s was lower than that observed in patients who
initiated treatment in the 1970s. Although patients in
the 1970s group were maintained on higher serum lith-
ium levels, no decrease in the effectiveness of treatment
was observed in the 1980s group.
Several studies have evaluated long-term outcomes in
patients who began with lithium treatment but contin-
ued with various treatments other than lithium in the
naturalistic setting. A recent study by Licht and co-
workers found an unsatisfactory outcome after 15 years
(Licht et al. 2008); however, their follow-up was based
on registry data that did not contain information on
whether patients had continued to receive lithium. As a
result, their findings do not allow inferences on the ef-
fectiveness of long-term lithium treatment.
Our study was not concerned with the efficacy or ef-
fectiveness of lithium, both of which have been demon-
strated in a substantial body of literature. The use of the
MI as our outcome measure did not allow us to com-
pare the pre-index and post-index course of illness, be-
cause the MI requires prospective follow-up to obtain
valid results. Retrospective data (e.g., from patient his-
tories) are insufficient in this regard.
The present study also differs from other investiga-
tions regarding the indication for starting lithium
prophylaxis. Most studies which have been performed
during the last decade included patients within a broader
definition of bipolar disorder and patients with anepisodic pattern of illness are systematically underrepre-
sented (Coryell 2009; Grof et al. 1995; Goodwin 1999;
Gershon et al. 2009). The lithium clinics involved in this
study, however, follow the Kraepelinian tradition of diag-
nosing bipolar disorder. As a result, it is conceivable that
most of the patients in our sample were bipolar in the
traditional and narrow sense of the term.
In addition, many of the newer studies perform ana-
lyses that use time-to-new-episode or time-to-new-
rehospitalization or hazard ratios for relapse as the main
outcome measure for long-term prophylactic effective-
ness (Bowden et al. 2003; Tohen et al. 2005; Viguera
et al. 2001; Geddes et al. 2010; Suppes et al. 2009). Al-
though this type of analysis is well suited to relatively
short trials that aim at proving a single drug's efficacy, it
is inappropriate for long-term maintenance studies be-
cause it fails to discriminate between different types of
response. Outcome criteria such as relapse or recurrence
do not afford proper assessment of the course of illness
in patients who show substantial clinical improvement
but still experience episodes and thus fail to consider a
patient-focused perspective which is relevant for clinical
practice (Murru et al. 2011). Given that bipolar disorder
is characterized by wide variations in the length and se-
verity of episodes, the MI is an outcome measure which
allows different forms of response and clinical course to
be distinguished from one another in a precise fashion.
This can be seen in an investigation of lithium mainten-
ance treatment over a maximum of 15 years in a small
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though the MItotal remained stable throughout the study
period, the analysis of the absolute number of recur-
rences failed to produce any conclusive results because
of the general shift over the study period from out-
patient to inpatient treatment (Berghöfer et al. 1996).
The outcome measure ‘burden of illness’ which is com-
parable to the MI and uses a life chart method combin-
ing severity and duration of episodes has recently been
presented by Backlund and coworkers in a long-term
evaluation (Backlund et al. 2009 ).
In summary, the MI appears to be the most accurate
approach to describing chronic illnesses and would
therefore seem to be a much more appropriate tool than
survival analysis. Extended Cox regression models can
provide a more accurate description of chronic illnesses
because they focus on multiple recurrences rather than
time to first recurrence (Pfennig et al. 2010).
The results of the present analysis are in agreement
with those of several studies from the same group of re-
searchers and, in part, derived from the same patient
data. Berghöfer et al. used the MI to report on long-
term response in a subgroup of bipolar patients over a
maximum of 15 years (Berghöfer et al. 1996), as noted
above, and in another study over a maximum of 20 years
(Berghöfer and Müller-Oerlinghausen 2000). In both
studies, which included a subset of subjects from the
present investigation, the severity and duration of recur-
rences remained stable, and even decreased, over the ob-
servation period, albeit in small sample sizes. Two
recent reviews also support our finding that the effect-
iveness of lithium prophylaxis does not diminish over
time (Burgess et al. 2001; Kleindienst et al. 1999).
There has been some controversy as to whether the
length of time between illness onset and the start of
prophylactic treatment (i.e., latency) may influence pa-
tients' response to long-term treatment (Franchini et al.
1999). For this reason, we included latency of prophylac-
tic treatment in our analysis. However, like the present
analysis, other recent studies have not shown any associ-
ation between negative outcomes and latency (Baethge
et al. 2003a; Baethge et al. 2003b; Baldessarini et al. 2003).
Our study has several methodological limitations.
Firstly, the severity of episodes may have been rated dif-
ferently at the various centers due to the use of different
symptom thresholds for the initiation of treatment. This
clearly has the potential to affect which symptoms were
rated as degree 2. In addition, with multiple countries
and cultures involved, treatment selection may have var-
ied depending on factors such as the healthcare system,
the regional facilities available, and individual patient
preferences. As in any long-term investigation, patients
who receive up to 20 years of treatment were seen by a
large number of therapists with varying degrees oftraining. However, the influence of the abovementioned
factors may have been mitigated by the similar tradition
of diagnosis and treatment followed by all of the centers
that participated in the present study. More specifically,
the centers agreed on a common treatment concept that
gives preference to lithium monotherapy whenever pos-
sible as a means to avoid adverse events and drug-
induced cycling. In addition, there were no differences
in the MI between the centers. As a result, any center-
specific effect is likely to have been relatively small.
Secondly, the centers participating in the present study
were specialized academic outpatient clinics that, for the
most part, treated patients who required an above-
average amount of care. As such, a selection bias must
be assumed. It should be noted, however, that the use of
additional medication in our sample was quite low. Out
of 346 patients 152 (44%) had a mean co-medication
period of 22.4 out of 52 weeks (see Table 2), which indi-
cates that patients with a severe course of illness were
unlikely to have been overrepresented. The use of co-
medication was higher in other long-term observations
(e.g., 15). Because the present study is not an epidemio-
logical investigation with a representative sample of bi-
polar patients, our results cannot be extrapolated to the
general population of these patients; similarly, it is not
possible to fully apply our results to routine psychiatric
practice.
Thirdly, this analysis did not count affective symptoms
that had been rated as degree 1 (i.e., symptoms that do
not require additional treatment). Recently, a substantial
number of studies have been conducted to assess
interepisodic subthreshold symptoms, such as cognitive
or affective impairment. It seems unlikely, however, that
including degree 1 symptoms in the analysis would sig-
nificantly affect the long-term stability shown by the MI.
Fourthly, a substantial number of patients dropped out
of the study before completing 20 years of treatment,
and these subjects were not followed up. One might
argue that analyzing only those patients who remained
on lithium treatment caused a selection toward higher
stability, because non-responders may have switched to
a different long-term medication or treatment setting.
However, it should be noted that the mean MI in pa-
tients who dropped out was not higher during their last
year of follow-up than it had been during the preceding
years. This indicates that the course of illness in subjects
who left the study was no worse than those who contin-
ued lithium treatment.
As a final consideration, it should be pointed out that
the MI does not fully reflect the effects and benefits of
lithium in individual patients. A patient might show a
higher MI than another patient during lithium treatment
but might nevertheless experience a substantially greater
reduction in his or her affective morbidity after starting
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may have spent 15 days in the hospital (degree 3) and
may show no other illness burden during a period of 1
year, alternatively the patient could have received ap-
proximately 23 days of treatment in addition to lithium
for any affective symptoms without having spent any
time in the hospital (degree 2). To show individual bene-
fits, data comparing pre- and post-treatment MI would
have been helpful. However, assessing the initial effect-
iveness of lithium treatment was not the primary focus
of our analysis.
Conclusions
Our results show that patients who met both the clas-
sical ICD-8 and ICD-9 criteria, as well as the DSM IV
criteria, for bipolar disorder had a stable course of illness
during long-term lithium treatment.
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